Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Matsuura

Showing results (1-10 of 160) with videos related to

Pageof 16
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 14, 2015
[Natural history of hepatitis C virus infection]Kentaro Matsuura, Yasuhito Tanaka
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 15, 2017
Efficacy of regimens combining direct acting antiviral agents for hepatitis C virus recombinant form RF1_2k/1bKentaro Matsuura, Yasuhito Tanaka
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 22, 2011
[Relation of IL28B gene polymorphism to chronic hepatitis C]Kentaro Matsuura, Yasuhito Tanaka
Journal of Medical Virology|July 28, 2015
Host genetic variants influencing the clinical course of hepatitis C virus infectionKentaro Matsuura, Yasuhito Tanaka
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 14, 2017
Host genetic variations associated with disease progression in chronic hepatitis C virus infectionKentaro Matsuura, Yasuhito Tanaka
Nihon Rinsho. Japanese Journal of Clinical Medicine|February 6, 2016
[Analysis of interferon-stimulated genes expression associated with early elimination of HCV RNA]Kentaro Matsuura, Sayuki Iijima, Yasuhito Tanaka
Journal of Medical Virology|August 11, 2015
Host genetic variants influencing the clinical course of hepatitis B virus infectionKentaro Matsuura, Masanori Isogawa, Yasuhito Tanaka
Journal of Gastroenterology and Hepatology|December 12, 2013
Role of IL28B for chronic hepatitis C treatment toward personalized medicineKentaro Matsuura, Tsunamasa Watanabe, Yasuhito Tanaka
Gastroenterology|November 4, 2017
ReplyKentaro Matsuura, Masayuki Kurosaki, Yasuhito Tanaka
Journal of Biopharmaceutical Statistics|January 31, 2023
Optimal dose escalation methods using deep reinforcement learning in phase I oncology trialsKentaro Matsuura, Kentaro Sakamaki, Junya Honda, et al.
Pageof 16

Showing results (1-10 of 160) with videos related to

Sort By:
Pageof 16
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 14, 2015
[Natural history of hepatitis C virus infection]Kentaro Matsuura, Yasuhito Tanaka
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 15, 2017
Efficacy of regimens combining direct acting antiviral agents for hepatitis C virus recombinant form RF1_2k/1bKentaro Matsuura, Yasuhito Tanaka
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 22, 2011
[Relation of IL28B gene polymorphism to chronic hepatitis C]Kentaro Matsuura, Yasuhito Tanaka
Journal of Medical Virology|July 28, 2015
Host genetic variants influencing the clinical course of hepatitis C virus infectionKentaro Matsuura, Yasuhito Tanaka
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 14, 2017
Host genetic variations associated with disease progression in chronic hepatitis C virus infectionKentaro Matsuura, Yasuhito Tanaka
Nihon Rinsho. Japanese Journal of Clinical Medicine|February 6, 2016
[Analysis of interferon-stimulated genes expression associated with early elimination of HCV RNA]Kentaro Matsuura, Sayuki Iijima, Yasuhito Tanaka
Journal of Medical Virology|August 11, 2015
Host genetic variants influencing the clinical course of hepatitis B virus infectionKentaro Matsuura, Masanori Isogawa, Yasuhito Tanaka
Journal of Gastroenterology and Hepatology|December 12, 2013
Role of IL28B for chronic hepatitis C treatment toward personalized medicineKentaro Matsuura, Tsunamasa Watanabe, Yasuhito Tanaka
Gastroenterology|November 4, 2017
ReplyKentaro Matsuura, Masayuki Kurosaki, Yasuhito Tanaka
Journal of Biopharmaceutical Statistics|January 31, 2023
Optimal dose escalation methods using deep reinforcement learning in phase I oncology trialsKentaro Matsuura, Kentaro Sakamaki, Junya Honda, et al.
Pageof 16